

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Founded and led for 30 years by physician-scientists, our unique ability to consistently translate science into medicine has led to numerous FDA-approved treatments and over sixteen product candidates, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary *VelociSuite*® technologies and ambitious initiatives such as the Regeneron Genetics Center®, one of the largest genetics sequencing efforts in the world.

GENERAL COMPANY INFORMATION

- Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
- More than 7,000 employees in the U.S. and EU
- Current annualized R&D spending in excess of \$2 billion; partially supported through research collaborations

LOCATIONS

- Tarrytown, NY: Corporate and Research & Development headquarters
- Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities
- Sleepy Hollow, NY and Basking Ridge, NJ: Satellite offices
- Dublin, Ireland and London, UK: EU business offices


LEADERSHIP TEAM

- **Leonard S. Schleifer, MD, PhD**
Founder, President and Chief Executive Officer
- **George D. Yancopoulos, MD, PhD**
Founding Scientist, President and Chief Scientific Officer
+ *Member, National Academy of Sciences*
- **P. Roy Vagelos, MD**
Chairman of the Board
+ *Former Chief Executive Officer and Chairman of the Board, Merck & Co.*
+ *Member, National Academy of Sciences*
- **Board of Directors** includes two Nobel Laureates and seven members of the National Academy of Sciences

FDA-APPROVED & MARKETED MEDICINES



Please see Full Prescribing Information including Boxed WARNING at www.kevzara.com



CLINICAL PRODUCT CANDIDATES



REGN1908-1909
Fc d 1 Antibody | Allergic diseases

REGN4659*
CTLA4 Antibody | Cancer

REGN4018*
MUC16xCD3 Antibody | Cancer

POZELIMAB
C5 Antibody | Paroxysmal nocturnal hemoglobinuria

GARETOSMAB + TREVOCRUMAB
Activin A Antibody + GDF8 Antibody
 Muscle-wasting diseases

REGN-EB3
Antibody to Ebola virus
 Ebola virus infection

REGN3048-3051
Antibody to Middle Eastern Respiratory Coronavirus | MERS-CoV infection

CEMPIPLIMAB*
PD-1 Antibody | Cancer

REGN1979
CD20xCD3 Antibody | Cancer

REGN3767*
LAG-3 Antibody | Cancer

CEMPIPLIMAB + REGN1979
PD-1 Antibody + CD20xCD3 Antibody
 Cancer

CEMPIPLIMAB + REGN3767*
PD-1 Antibody + LAG-3 Antibody | Cancer

REGN4461
LEPR Antibody
 Lipodystrophy and obesity

DUPILUMAB*
IL-4R Antibody
 Eosinophilic esophagitis

SARILUMAB*
IL-6R Antibody | Polyarticular-course juvenile idiopathic arthritis

REGN3500*
IL-33 Antibody | Asthma

EVINACUMAB
ANGPTL-3 Antibody | Refractory hypercholesterolemia (both HeFH and non-FH)

GARETOSMAB
Activin A Antibody | Fibrodysplasia Ossificans Progressiva (FOP)

CEMPIPLIMAB*
PD-1 Antibody | Cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC)

DUPILUMAB*
IL-4R Antibody | Atopic dermatitis in pediatrics and adolescents, asthma in adults and adolescents, pediatric asthma, nasal polyps

ALIROCUMAB*
PCSK9 Antibody | Hypercholesterolemia, LDL cholesterol reduction and prevention of cardiovascular events

EVINACUMAB
ANGPTL-3 Antibody | Homozygous familial hypercholesterolemia (HoFH)

CEMPIPLIMAB*
PD-1 Antibody | Non-small cell lung cancer, cervical cancer

AFLIBERCEPT
VEGF-Trap | Non-proliferative diabetic retinopathy (NPDR) without DME

FASINUMAB†
NGF Antibody | Osteoarthritis pain

■ IMMUNOLOGY & INFLAMMATORY DISEASES
 ■ CARDIOVASCULAR/METABOLIC DISEASES
 ■ ONCOLOGY
 ■ INFECTIOUS DISEASES
 ■ OPHTHALMOLOGY
 ■ PAIN
 ■ RARE DISEASES

* IN COLLABORATION WITH SANOFI

* IN COLLABORATION WITH TEVA AND MITSUBISHI TANABE

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

LEADERS IN TECHNOLOGY

- **Fully human monoclonal antibodies:** Regeneron has developed a suite of patented technologies (*VelociSuite*®), including *VelociGene*®, *VelociImmune*® and *VelociMab*®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.
- **Fusion proteins:** Our novel and patented “Trap” fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.
- **Regeneron Genetics Center:** A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

Fortune: 100 Best Companies to Work For, 2018
Civic 50: Most Community-Minded Companies, 2017
MIT Technology Review: Top 10 Smartest Companies, 2017
Science: #1 Top Employer, 2017



Forbes: World's Most Innovative Companies, 2013-2018
Great Places to Work: Best Workplace in Ireland, 2017
Barron's: World's Best CEOs, 2016
Scrip Award: R&D Team of the Year, 2016

To learn more about us, please visit:

REGENERON.COM

@REGENERON

Science to Medicine, VelociGene, VelociSuite, VelociImmune, VelociMab, ARCALYST and EYLEA are registered trademarks of Regeneron Pharmaceuticals, Inc. in the U.S.; PRALUENT, DUPIXENT and KEVZARA are registered trademarks of Sanofi. © 2018 Regeneron Pharmaceuticals, Inc. 08/18